Jeremy Cubert, Esq. helps investors in the Life Science assess the scientific validity and commercial viability of the intellectual property assets underlying proposed investments. From a quick assessment to spot red flags that trigger a no-go decision, to in-depth evaluations of large, complicated IP portfolios, Jeremy helps investors eliminate investments that exceed their risk profile and, perhaps more importantly, enable them to recognize high-potential investments whose viability, at first glance, may not have been apparent.
Jeremy is a partner at Potomac Law Group, and a member of the firm’s Intellectual Property Practice Group. With over 20 years of experience in patent law with an emphasis in life sciences, he assists companies in all aspects of obtaining and managing their intellectual property portfolios. He has extensive experience in patent prosecution, due diligence and analysis of intellectual property portfolios and I regularly counsel clients regarding the acquisition and licensing of intellectual property assets. He regularly work directly with scientists and professionals at academic institutions, biotechnology companies, and Fortune 500 companies to develop intellectual property development and management plans.
Before joining Potomac Law Group, Jeremy was a partner with VLP Law Group, the Clinical Technology Transfer Group and in the Intellectual Property Group of Dickstein Shapiro. He also also served as a staff attorney with the Federal Trade Commission and a Technology Transfer Specialist at the National Cancer Institute (NCI) at the National Institutes of Health (NIH), where he managed the intellectual property portfolio for nine institutes at the NIH.